Riyadh: CEO of the Saudi Food and Drug Authority (SFDA) Dr. Hisham Aljadhey convened with several chief executives and representatives from local and international pharmaceutical companies at the SFDA headquarters to discuss pivotal issues and potential opportunities that aim to foster growth and support within the Kingdom’s pharmaceutical sector.

According to Saudi Press Agency, this meeting is part of SFDA’s continuous efforts to enhance partnerships with the private sector and establish direct communication channels with industry representatives. It served as a platform for addressing current challenges, exploring future opportunities, and exchanging perspectives on strengthening investment, innovation, and competitiveness in the Saudi pharmaceutical market.

The discussions were centered around regulatory strategies and enablers that create a sustainable and attractive investment environment, aligning with the objectives of Saudi Vision 2030. This initiative is designed to reinforce the Kingdom’s status as a leading regional and global hub for the pharmaceutical industry.

Participants examined the obstacles facing the private sector, proposing practical and innovative solutions to surmount them, with the aim of ensuring continued progress and sustainable growth in this crucial industry.

This meeting underscores SFDA’s commitment to transparency and active engagement with its partners, aiming to foster a collaborative environment between the public and private sectors. It also plays a role in achieving the objectives of the Health Sector Transformation Program, a key initiative of Vision 2030, and supports SFDA’s mission to protect public health by ensuring the availability of safe, effective, and high-quality medicines for society.